drugset / Trial / NCT03431688

Tailored Therapy for Clarithromycin-Resistant H. Pylori

NCT03431688

Completed 782 enrolled Kangdong Sacred Heart Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

Timeline

Start
2018-10-01
Primary completion
2020-10-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified
Comparator Bismuth Potassium Citrate Unknown
Comparator tetracyclin Unknown
Comparator metonidazole Unknown